(Q57912405)

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021

The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021

Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021

The natural history of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021

Nuclear magnetic resonance imaging of the brain in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021

Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021

Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021

Treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021

Interferons in the treatment of multiple sclerosis: do they prevent the progression of the disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021

A brief history of the use of interferons as treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021

Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021

Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021

Efficient constitutive production of human fibroblast interferon by hamster cells transformed with the IFN-beta 1 gene fused to an SV40 early promoter.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021

Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021

"Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021

Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021

A referendum on clinical trial research in multiple sclerosis: the opinion of the participants at the Jekyll Island workshop

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021

Serum interferon beta-1a (Avonex) levels following intramuscular injection in relapsing-remitting MS patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903334-0

7 January 2021